

Kahimmune Therapeutics

Re-exploring the Cancer Immuno-peptidome

Company Overview

Kahimmune Therapeutics is a pioneering biotech company founded in November 2025 as a spin-off from Gustave Roussy, Europe's leading cancer center. The company is developing next-generation immuno-oncology therapies based on a breakthrough understanding of the **“dark genome”** and its role in immune regulation.

Scientific Breakthrough

- 98% of the human genome (the “dark genome”) does not encode proteins but plays a key biological role
- Kahimmune's founders uncovered how this unexplored genomic space contributes to the **cancer immuno-peptidome**
- Discovery of **Pioneer Translation Products (PTPs)**: a novel and vast source of tumor neoantigens

👉 This creates a **new paradigm** for identifying previously hidden therapeutic targets.

Therapeutic Approach

Kahimmune is developing **Companion Neoantigen Therapies (CNTs)**:

- mRNA-based therapies used in **combination with existing treatments**
- Designed to enhance **T cell-mediated anti-tumor response**
- Positioned as **synergistic, high-value add-ons**

Key advantages vs individualized neoantigen therapies:

- Scalable “off-the-shelf” approach
- Reduced dependence on patient-specific tumor biopsies
- Broader applicability

Pipeline Focus

- **KAH-001**: combinations with anti-VEGF / PD-1 for colorectal and pancreatic cancer
- **KAH-002**: radiotherapy combinations for lung cancer
- **KAH-003**: combinations with T cell engagers (TCEs) for solid tumors

Partnering Opportunity

Kahimmune is actively seeking partnerships to:

- Advance its CNT pipeline
- Explore new applications of Kahinomics™ (e.g., TCRs, TCEs)